文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

吸入性抗生素治疗重症监护室有创通气患者肺炎:随机临床试验的荟萃分析及试验序贯分析

Inhaled antibiotics for treating pneumonia in invasively ventilated patients in intensive care unit: a meta-analysis of randomized clinical trials with trial sequential analysis.
PubMed 文献 · Crit Care · 2024-11-25
一句话结论在重症监护室有创通气肺炎患者中,辅助吸入抗生素与更高的微生物清除率相关(OR 2.63,低证据质量),但未改善临床恢复和生存,且增加支气管痉挛风险(OR 3.15,高证据质量)。

该荟萃分析纳入11项随机对照试验共1472例重症监护室有创通气肺炎患者,比较辅助雾化抗生素与单纯静脉抗生素或静脉抗生素联合雾化安慰剂。主要终点为治疗后微生物清除率,结果为吸入组优于对照组(OR 2.63,95%CI 1.36-5.09;低证据质量),试验序贯分析证实结果可靠。次要终点中,雾化抗生素增加支气管痉挛风险(OR 3.15,95%CI 1.33-7.47;高证据质量),而肾毒性、临床恢复、ICU及住院生存率(无论是否为多重耐药菌所致肺炎)组间无差异。作者结论认为辅助吸入抗生素与更高的微生物清除率相关,但与临床恢复和生存无关。

要点

  • 在ICU有创通气肺炎患者中,辅助吸入抗生素较对照提高微生物清除率(OR 2.63,95%CI 1.36-5.09;低证据质量),试验序贯分析证实结果可靠。
  • 雾化抗生素增加支气管痉挛风险(OR 3.15,95%CI 1.33-7.47;高证据质量)。
  • 肾毒性、临床恢复、ICU及住院生存率(无论是否为多重耐药菌所致肺炎)组间无差异。
  • 主要终点证据质量为低,且存在高发表偏倚风险。
  • 作者结论:辅助吸入抗生素与更高的微生物清除率相关,但未改善临床恢复和生存。

适用人群与场景

  • 重症监护室(ICU)中诊断为肺炎并接受有创机械通气的成人危重症患者。
  • 纳入的随机对照试验比较雾化抗菌治疗(吸入组)与静脉抗菌治疗或静脉抗菌治疗联合雾化安慰剂(对照组)。

红旗征与不能漏的情况

  • 雾化抗生素增加支气管痉挛风险(OR 3.15,95%CI 1.33-7.47;高证据质量)。

研究设计与关键结果

  • 研究设计:随机对照试验的荟萃分析,纳入11项RCT共1472例ICU有创通气肺炎患者。
  • 主要终点:微生物清除率,吸入组优于对照组(OR 2.63,95%CI 1.36-5.09;低证据质量),试验序贯分析证实结果可靠。
  • 次要终点:支气管痉挛风险吸入组高于对照组(OR 3.15,95%CI 1.33-7.47;高证据质量)。
  • 次要终点:肾毒性、临床恢复、ICU及住院生存率(无论是否为多重耐药菌所致肺炎)组间无差异。
  • 作者结论:与单纯静脉治疗相比,辅助吸入抗生素与更高的微生物清除率相关(低GRADE证据质量且高发表偏倚风险),但与临床恢复和生存无关。

证据类型、等级与局限

  • 证据类型:随机对照试验的荟萃分析,系统检索Medline、Embase和Scopus(从建库至2024年9月20日,PROSPERO-CRD592906),采用GRADE框架进行定性分析,采用I²统计量评估异质性,采用试验序贯分析(TSA)评估可靠性。
  • 主要终点证据质量:低。
  • 支气管痉挛证据质量:高。
  • 局限:高发表偏倚风险(原文 conclusions 提及 high risk of publication bias)。

对床旁实践的改变

  • 作者认为:在ICU有创通气肺炎患者中,与单纯静脉治疗相比,辅助吸入抗生素与更高的微生物清除率相关,但与临床恢复和生存无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of inhaled antibiotics for treating pneumonia in invasively ventilated patients offers a direct approach, allowing for high local concentrations of the drug in the lower respiratory tract while simultaneously reducing systemic toxicity. However, the real efficacy and safety of nebulized antibiotics remain unclear. The aim of the present is to assess among critically adult patients with pneumonia and invasive ventilation, whether receiving adjuvant inhaled antibiotics improves the rate of microbiological eradication.

METHODS: A comprehensive literature search of randomized clinical trials (RCTs) was conducted (from inception until September 20, 2024, PROSPERO-CRD592906) across Medline, Embase, and Scopus. Randomized controlled trials, enrolling intensive care units (ICU) patients with pneumonia and comparing nebulized antimicrobial therapy (inhaled group) with intravenous antimicrobial treatment or intravenous antimicrobial therapy plus inhaled placebo (control group), were included. The primary outcome was the rate of microbiological eradication after treatment. Secondary outcomes were the rate of clinical recovery, the incidence of drug-related adverse events, ICU and hospital mortality. A qualitative analysis was conducted according to the GRADE framework. Data were pooled using an odds-ratio analysis. The heterogeneity and reliability of our results were evaluated using the I2-statistic and trial sequential analysis (TSA), respectively.

RESULTS: A total of 11 RCTs (1472 patients) met the inclusion criteria. Compared to controls, the use of adjuvant inhaled antibiotics determined a greater rate of microbiological eradication (OR 2.63, 95% CI 1.36-5.09; low certainty of evidence). The TSA confirmed the reliability of our primary outcome. Moreover, nebulized antibiotics increased the risk of bronchospasm (OR 3.15, 95% CI 1.33-7.47; high evidence), while nephrotoxicity, clinical recovery, ICU and hospital survival (either in the case of pneumonia caused by MDR bacteria or not) were not different between groups.

CONCLUSIONS: In conclusion, compared to the sole intravenous therapy, the use of adjuvant inhaled antibiotics for treatment of pneumonia in invasively ventilated critically ill patients was associated with a greater incidence of microbiological eradication (low GRADE and high risk of publication bias), but not with clinical recovery and survival.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Sella N, Pettenuzzo T, De Cassai A, et al. Inhaled antibiotics for treating pneumonia in invasively ventilated patients in intensive care unit: a meta-analysis of randomized clinical trials with trial sequential analysis. Crit Care. 2024. PMID: 39587607. doi:10.1186/s13054-024-05159-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。